Targeting of liposomes to accessible cells in vivo.
Gregoriadis
G
G
Senior
J
J
Wolff
B
B
Kirby
C
C
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000954:Antigens, Surface / Q000276:immunology; D001761:Bleomycin / Q000008:administration & dosage; D002460:Cell Line; D002784:Cholesterol; D007074:Immunoglobulin G / Q000627:therapeutic use; D007518:Isoantibodies / Q000627:therapeutic use; D008075:Lipoproteins, HDL; D008081:Liposomes / Q000008:administration & dosage* / Q000378:metabolism; D008657:Metabolic Clearance Rate; D051379:Mice; D010539:Permeability; D014677:Pharmaceutical Vehicles; D010713:Phosphatidylcholines; D011956:Receptors, Cell Surface / Q000378:metabolism; D013109:Sphingomyelins; D013329:Structure-Activity Relationship; D018800:Thy-1 Antigens
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D007074:Immunoglobulin G; D007518:Isoantibodies; D008075:Lipoproteins, HDL; D008081:Liposomes; D014677:Pharmaceutical Vehicles; D010713:Phosphatidylcholines; D011956:Receptors, Cell Surface; D013109:Sphingomyelins; D018800:Thy-1 Antigens; C039707:galactose receptor; D001761:Bleomycin; D002784:Cholesterol